NeutralLOW severityHealthcare & Pharma7d ago

Arvinas vp David Loomis sells $1,475 in stock

Arvinas vp David Loomis sells $1,475 in stock — $ARVN one-month chart
$ARVN daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

$ARVN is near its 52-week low, trading at $6.92, just a tenth above its 52-week low of $6.33, and closed the session up 2.37%. Recent coverage has been neutral, with most attention arriving in the last week, and the Health Care sector shows calm today.

Written by Wook AI Nov 10, 10:35 PM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about ARVN. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · arvinasEvent risk Low

Nothing reported about arvinas across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 67% a year
Now $6.77Week $6.13–$7.41 (±9.5%)Month $5.46–$8.08 (±19.4%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: The headline zeroes in on $1,475 — a single number, but it's the tip of a much larger iceberg. Context matters, and the trend behind it tells the real story.
  • How the stock is trading: $ARVN -0.73% in the latest session.
  • Timing: It came out after the closing bell. The session change shown was settled before the story existed, and the next session is the first that could react.
Amount$1,475

Where the stock stands

Arvinas ($ARVN) slipped 0.73% to $6.77 in the latest session. Over the past month it is down 6.7%. That leaves it 53% below its 52-week high of $14.51 and 7.0% above its low of $6.33, close to the bottom of its range. The year's high was 2.3 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 3, 2026), $ARVN lost $53.9M over the quarter to Sep 30, 2026 on revenue of $500K (-99.8% QoQ). Operations used $127.9M of cash over the nine months to Sep 30, 2026 — about $14.3M a month — against $88.0M in cash on Sep 30, 2026. At that pace the cash covers about 6 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. It carried $400K of debt against $88.0M of cash on Sep 30, 2026 — net cash of $87.6M. Its most recent filings before this story: 10-Q on Nov 3, 2026, 8-K on Nov 3, 2026, 10-Q on Aug 4, 2026. Figures are as filed with the SEC; the $ARVN page has the full statements.

How much coverage it is getting

Wook has no other story on Arvinas from the last 30 days, so there is no recent run to compare this one with.

The bigger picture

In healthcare, timing is everything — trial results, FDA rulings, and pricing shifts can send stocks soaring or sinking. One event can shift a drugmaker's fate, while a policy change can ripple across the whole sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

What to watch next

The $ARVN page has the full chart, filings, and valuation models. Since one outlet dominates the coverage, checking another is the fastest way to see if the story is confirmed or just repeated. And Wook AI is here to help with the math — how far $ARVN has come, or how this week's coverage stacks up.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on November 9, 2026. $ARVN has moved +1.65% ($6.66 to $6.77). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy